We finally have a more natural method to kill cancer.
A study from Cold Spring Harbor Laboratory suggests that a vitamin K precursor, menadione, may offer a highly targeted way to kill prostate cancer cells.
Unlike traditional treatments that push cancer into dormancy, menadione acts as a pro-oxidant, disrupting a key lipid called PIP. This lipid helps cells manage waste, and without it, cancer cells become overwhelmed and ultimately burst.
The study, published in Science, demonstrated significant tumor suppression in both mice and human cancer cells. Researchers believe this method could offer a safer and more definitive resolution for prostate cancer while minimizing the risk of resistance.
Beyond cancer, menadione also shows promise in treating X-linked myotubular myopathy, a severe genetic muscle disorder. Importantly, menadione’s safety profile appears favorable, as it is commonly used in animal feed to support vitamin K production.